Palmar plantar erythrodysesthesia physical examination: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 6: Line 6:
==Overview==
==Overview==


Physical examination of patients with palmar plantar erythrodysesthesia depends on the grade of the disease. Determination of toxicity grading of PPE requires both visual assessment and patient description of symptoms. Skin findings include erythema, edema, hyperkeratosis, peeling, blisters, bleedings, and fissures.
[[Physical examination]] of patients with PPE depends on the grade of the disease. Determination of [[toxicity]] grading of PPE requires both visual assessment and patient description of [[Symptom|symptoms]]. [[Skin]] findings include [[erythema]], [[edema]], [[hyperkeratosis]], peeling, [[Blister|blisters]], [[bleeding]], and [[Fissure|fissures]].


==Physical Examination==
==Physical Examination==


Physical examination of patients with palmar plantar erythrodysesthesia depends on the grade of the disease. Determination of toxicity grading of PPE requires both visual assessment and patient description of symptoms.  
[[Physical examination]] of [[Patient|patients]] with PPE depends on the grade of the disease. Determination of [[toxicity]] grading of PPE requires both visual assessment and patient description of [[Symptom|symptoms]].  


===Appearance of the Patient===
===Appearance of the Patient===
Line 16: Line 16:


===Vital Signs===
===Vital Signs===
*Vital signs are normal.  
*[[Vital signs]] are normal.


===Skin===
===Skin===
* Skin examination of patients with palmar plantar erythrodysesthesia depends on the grade of the disease. Determination of toxicity grading of PPE requires both visual assessment and patient description of symptoms.  
*[[Skin]] [[examination]] of [[patients]] with PPE depends on the grade of the [[disease]]. Determination of [[toxicity]] grading of PPE requires both visual assessment and patient description of symptoms.


* Physical findings include:<ref name="urlProtocol Development | CTEP">{{cite web |url=https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm |title=Protocol Development &#124; CTEP |format= |work= |accessdate=}}</ref>
* Physical findings include:<ref name="urlProtocol Development | CTEP">{{cite web |url=https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm |title=Protocol Development &#124; CTEP |format= |work= |accessdate=}}</ref>
 
**[[Erythema]]
** Erythema
**[[Edema]]
** Edema
**[[Hyperkeratosis]]
** Hyperkeratosis
** Peeling
** Peeling  
**[[Blister|Blisters]]
** Blisters
**[[Bleeding]]
** Bleeding
**[[Fissures]]
** Fissures


===HEENT===
===HEENT===
* HEENT examination of patients with palmar plantar erythrodysesthesia is usually normal.
* HEENT [[examination]] of [[patients]] with PPE is usually normal.


===Neck===
===Neck===
* Neck examination of patients with palmar plantar erythrodysesthesia is usually normal.
*[[Neck]] [[examination]] of [[patients]] with PPE is usually normal.


===Lungs===
===Lungs===
* Pulmonary examination of patients with palmar plantar erythrodysesthesia is usually normal.
*[[Pulmonary]] [[examination]] of [[Patient|patients]] with PPE is usually normal.


===Heart===
===Heart===
* Cardiovascular examination of patients with palmar plantar erythrodysesthesia is usually normal.
*[[Cardiovascular]] [[examination]] of [[patients]] with PPE is usually normal.


===Abdomen===
===Abdomen===
* Abdominal examination of patients with palmar plantar erythrodysesthesia is usually normal.
*[[Abdominal]] [[examination]] of [[patients]] with PPE is usually normal.


===Back===
===Back===
* Back examination of patients with palmar plantar erythrodysesthesia is usually normal.
*[[Back]] [[examination]] of [[patients]] with PPE is usually normal.


===Genitourinary===
===Genitourinary===
* Genitourinary examination of patients with palmar plantar erythrodysesthesia is usually normal.
*[[Genitourinary]] [[examination]] of [[patients]] with PPE is usually normal.


===Neuromuscular===
===Neuromuscular===
* Neuromuscular examination of patients with palmar plantar erythrodysesthesia is usually normal. Rarely, sensory impairment in the extemities may be seen.  <ref name="pmid11034047">{{cite journal| author=Hui YF, Cortes JE| title=Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin. | journal=Pharmacotherapy | year= 2000 | volume= 20 | issue= 10 | pages= 1221-3 | pmid=11034047 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11034047  }} </ref> <ref name="urlwww.oncologynurseadvisor.com">{{cite web |url=https://www.oncologynurseadvisor.com/home/departments/ce-courses/prevention-and-management-of-hand-foot-syndromes/ |title=www.oncologynurseadvisor.com |format= |work= |accessdate=}}</ref>
*[[Neuromuscular]] [[examination]] of [[patients]] with PPE is usually normal. Rarely, [[sensory]] [[impairment]] in the [[extremities]] may be seen.  <ref name="pmid11034047">{{cite journal| author=Hui YF, Cortes JE| title=Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin. | journal=Pharmacotherapy | year= 2000 | volume= 20 | issue= 10 | pages= 1221-3 | pmid=11034047 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11034047  }} </ref> <ref name="urlwww.oncologynurseadvisor.com">{{cite web |url=https://www.oncologynurseadvisor.com/home/departments/ce-courses/prevention-and-management-of-hand-foot-syndromes/ |title=www.oncologynurseadvisor.com |format= |work= |accessdate=}}</ref>


==References==
==References==
<br />
{{reflist|2}}
{{reflist|2}}
[[Category:Needs content]]
[[Category:Needs content]]

Revision as of 18:57, 16 July 2019

Palmar plantar erythrodysesthesia Microchapters

Home

Overview

Historical perspective

Classification

Pathophysiology

Causes

Differentiating Palmar plantar erythrodysesthesia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Palmar plantar erythrodysesthesia physical examination On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia physical examination

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Palmar plantar erythrodysesthesia physical examination

CDC on Palmar plantar erythrodysesthesia physical examination

Palmar plantar erythrodysesthesia physical examination in the news

Blogs on Palmar plantar erythrodysesthesia physical examination

Directions to Hospitals Treating Palmar plantar erythrodysesthesia

Risk calculators and risk factors for Palmar plantar erythrodysesthesia physical examination

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mandana Chitsazan, M.D. [2]

Overview

Physical examination of patients with PPE depends on the grade of the disease. Determination of toxicity grading of PPE requires both visual assessment and patient description of symptoms. Skin findings include erythema, edema, hyperkeratosis, peeling, blisters, bleeding, and fissures.

Physical Examination

Physical examination of patients with PPE depends on the grade of the disease. Determination of toxicity grading of PPE requires both visual assessment and patient description of symptoms.

Appearance of the Patient

  • Patients with palmar plantar erythrodysesthesia usually appear normal.

Vital Signs

Skin

HEENT

Neck

Lungs

Heart

Abdomen

Back

Genitourinary

Neuromuscular

References

  1. "Protocol Development | CTEP".
  2. Hui YF, Cortes JE (2000). "Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin". Pharmacotherapy. 20 (10): 1221–3. PMID 11034047.
  3. "www.oncologynurseadvisor.com".